Bretisilocin, also known as GM-2505 or 5-fluoro-N-methyl-N-ethyltryptamine, is a serotonergic psychedelic tryptamine analogue under development as a treatment for major depressive disorder. It's a 5-fluorinated derivative of methylethyltryptamine (MET) and an analogue of dimethyltryptamine (DMT). The administration route for Bretisilocin is intravenous infusion.
2022: First Description in Literature
In 2022, Bretisilocin was first described in the scientific literature.
June 2025: Phase 2 Clinical Trials
In June 2025, Bretisilocin is in phase 2 clinical trials for the treatment of major depressive disorder, and a phase 2a trial has been completed, with the efficacy and safety data released.
August 2025: Acquisition by AbbVie
In August 2025, AbbVie acquired Bretisilocin from Gilgamesh Pharmaceuticals for up to $1.2 billion.
Trending
3 hours ago Riot Games Announces VCT 2027 Global Tour and Manila Pacific Cup Host
4 hours ago Denzel Washington's Historic Colonial Revival Mansion In Los Angeles
4 hours ago Steve Kerr Advises Warriors Fans on Managing Expectations for Steph Curry's Playing Schedule
5 hours ago Jennifer Connelly and Paul Bettany Discuss Their Longstanding Marriage and Professional Projects
5 hours ago Demi Moore Stuns Fans With Ageless Makeup-Free Glowing Complexion Photo
4 hours ago Alexander Bublik Faces Backlash After Racket Smashing Incident and Injury
Popular
Ilhan Omar is a prominent American politician currently serving as...
Ken Paxton is an American politician and lawyer serving as...
Elon Musk is a visionary entrepreneur and engineer known for...
Michael Joseph Jackson the King of Pop was a highly...
Jameis Winston is an American football quarterback currently playing for...
Cristiano Ronaldo widely considered one of the greatest footballers captains...